Organic Active Ingredients TRIZ Cases

Roughened polyester substrate prevents drug migration and eliminates primer discoloration while ensuring strong adhesion.

Cyclodextrin complexation solubilizes hydrophobic Salvinorin A, resolving water solubility constraints while preserving neuroprotective efficacy.

Oligomeric miRNA mimics delivered via lipid nanoparticles restore tumor suppressor activity in cancer cells.

Modular cyclization and salt conversion resolve synthesis efficiency and scalability bottlenecks.

Administering BCL6 inhibitors removes immunosuppressive 4PD1hi T cells, reducing severe immune-related toxicities during cancer treatment.

Laser ablation of boron nitride nanosheets creates porous tunnels that bypass interstitial pressure barriers to deliver BCL-2 inhibitors deep into solid tumors.

A synthesis apparatus mixes lipid and nucleic acid solutions in a channel to form particle-based therapeutics at the point of care.

Inhalable mist formulations concentrate antiviral agents at infection sites to reduce viral replication while minimizing systemic side effects.

Encoding JEV signal peptide with prME achieves sterilizing immunity at 20-fold lower dose and reduces viral load by 80%.

Difumarate monohydrate salt formation enhances bioavailability of histamine H3 receptor antagonists.

Three crystal forms and salt crystals of Compound I exhibit low hygroscopicity.

Melt extrusion creates solid ambroxol preparations with adjustable release profiles and high active ingredient content.

Nitrogen-filled headspace in the sachet prevents oxidative reactions that generate unpleasant odors during storage.

Circular RNAs encapsulated in lipid nanoparticles achieve sustained protein expression without genomic integration risks.

AAV9 vectors deliver IDUA genes to the central nervous system, addressing neurological symptoms in Mucopolysaccharidosis Type I.

Small molecule inhibitors block MutSβ mismatch repair activity, enabling stable genome edits and treating repeat expansion disorders.

Benzimidazole derivatives modify substituent groups on the core ring to optimize therapeutic effectiveness and resolve drug approval bottlenecks.

Composite ethyl cellulose coating prevents dose dumping and maintains stability across varying pH conditions.

Pyrido[1,2-a]pyrimidin-4-one derivatives lower mutant huntingtin protein levels to treat Huntington's disease.

Short interfering nucleic acid molecules mediate RNA interference to inhibit hepatitis B virus gene expression.

Selective P2Y6 receptor agonists reduce pathological plaque burden and improve cognitive function in neurodegenerative disease models.

Precise blending ratios of tyrosine, serine, alanine, aspartic acid, and glutamic acid reduce cognitive decline and fatigue caused by mental stress.

Low pH cysteine composition minimizes aluminum toxicity and prevents cystine precipitation.

Crystalline (R)-N-methylnaltrexone bromide blocks peripheral receptors to reduce gastrointestinal side effects while maintaining analgesic benefits.

Chemically modified BMP RNA drives bone regeneration while avoiding recombinant protein side effects.

Formula I compounds selectively inhibit FGFR kinases, overcoming resistance and off-target effects in cancer treatment.

Benzoxazine carbamate compounds antagonize RORgammaT transcriptional activity, reducing side effects in autoimmune disease treatment.

Cleaved bilirubin compounds activate PPARα to reduce adiposity, addressing the water solubility limits of native bilirubin.

Difluoromethyl-phenyl triazoles improve brain penetration and metabolic stability while reducing side effects.

Administering an anti-CD70 antibody overcomes venetoclax resistance by reducing leukemic stem cell concentration and improving remission rates.

Solid particle-displayed TAM targeting peptides reduce macrophage numbers and alter cytokine profiles to delay tumor growth in triple-negative breast cancer.

Bicyclic amine compounds inhibit cyclin-dependent kinase 2 to treat cancers with deregulated enzyme activity.

Formula IVA compounds inhibit cytochrome P450 monooxygenase to maintain therapeutic blood plasma levels and minimize viral resistance.

Elongated flexible solid drug composition injected into the suprachoroidal space avoids rapid lymphatic washout and reduces intraocular pressure.

5-substituted quinazolinones bypass efflux transporters to penetrate the blood-brain barrier and treat BRAF-associated brain metastases.

Threshold-based safety controls filter residual agents to prevent inaccurate drug administration during clinical workflows.

A dihydroquercetin and drone brood mixture enhances capillary permeability to support brain cell recovery.

Partial decarboxylation of isolated cannabis trichomes enables single-step mechanical pressing for cohesive hashish production.

Triphenylphosphonium-substituted azolium salts induce apoptosis in bladder cancer cells.

Acetate or histidine buffers maintain a 4.5 to 6.5 pH range, preventing thermal stress-induced protein aggregation and preserving monomer form.

Continuous intravenous infusion of anti-GD2 antibodies reduces complement-dependent cytotoxicity pain while sustaining tumor cell lysis.

Sequential chemotherapy and activated NK cell therapy eliminate differentiated tumor cells and resistant cancer stem cells.

Spirocyclic compounds selectively inhibit peripheral tryptophan hydroxylase 1 to reduce intestinal serotonin levels.

Pyrazolopyrimidine compounds inhibit hematopoietic progenitor kinase 1 activity to enhance antitumor immunity and treat autoimmune disorders.

Small hairpin RNA molecules feature a nucleotide insertion creating a stem kink to bind the RIG-I receptor.

Moisture permeation preventing pouches maintain 2000-5000 ppm water content in the adhesive layer, inhibiting discoloration and ensuring releasability.

Fosravuconazole L-lysine ethanolate achieves high complete cure rates while reducing recurrence and adverse events.